Fourth, it directs patient management (for example, antiviral treatment and screening for progressive hearing loss in infants with congenital CMV infection76, cardiovascular surveillance in FLNA-related and ARFGEF2-related PNVH77,78 or mTORC1 inhibition in patients with tuberous sclerosis complex (TSC))79. The gene discussed is ARFGEF2; the disease is tuberous sclerosis.